Date: 01st April, 2020

Corporate Relationship Department, BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
Mumbai-400 051

Dear Sir/Madam,

Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.
Ref: Stock Code: NSE: SHILPAMED/BSE-530549

We hereby inform that the Shilpa Medicare Ltd’s Finished Dosage Formulation Facility (Sterile and Non-sterile) located at S-20 to S-26, Pharmaceutical Formulations SEZ, TSIIC, Jadcherla, Telangana State, India has been issued EU GMP by Austrian Authority (AGES) for the inspection held during 13 to 17 Jan 2020. Shilpa Medicare Limited’s affiliates have registered it’s products (Oral solids & Injections) with European authorities for commercial distribution. The renewed EU GMP facilitates continued supply of products to European union.

This is for your information and doing the needful.

With Regards,

For SHILPA MEDICARE LIMITED

Sd/-
V.V.KRISHNA CHAITANYA
COMPANY SECRETARY
M.NO: 49415

Note: As permitted this letter is being submitted under Sd/- mode as per the government advisory on Covid -19 and as a part of safety measure.